Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCasa Sollievo della Sofferenza IRCCS

About this trial

Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs/10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq/AbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.

Eligibility criteria

Qualifiers

patients diagnosed with lung adenocarcinoma

treatment naive

undergoing primary surgery

Disqualifiers

patients with a previous history of cancer

previously treated by chemio/immuno/radio-therapy

Trial design

Treatments tested in this trial

  • Analysis of diagnostic biomarkers

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

Casa Sollievo della Sofferenza IRCCS

Lead sponsor

IRCCS Ospedale San Raffaele

Collaborator